Senescence Sensitivity of Breast Cancer Cells Is Defined by Positive Feedback Loop between CIP2A and E2F1
Open accessPublished version of a preprint
The DOI matches its Crossref record; 60 of the 62 references it cites were found in a registry or an index.
Abstract
Senescence induction contributes to cancer therapy responses and is crucial for p53-mediated tumor suppression. However, whether p53 inactivation actively suppresses senescence induction has been unclear. Here, we show that E2F1 overexpression, due to p53 or p21 inactivation, promotes expression of human oncoprotein CIP2A, which in turn, by inhibiting PP2A activity, increases stabilizing serine 364 phosphorylation of E2F1. Several lines of evidence show that increased activity of E2F1-CIP2A feedback renders breast cancer cells resistant to senescence induction. Importantly, mammary tumorigenesis is impaired in a CIP2A-deficient mouse model, and CIP2A-deficient tumors display markers of senescence induction. Moreover, high CIP2A expression predicts for poor prognosis in a subgroup of patients with breast cancer treated with senescence-inducing chemotherapy. Together, these results implicate the E2F1-CIP2A feedback loop as a key determinant of breast cancer cell sensitivity to senescence induction. This feedback loop also constitutes a promising prosenescence target for therapy of cancers with an inactivated p53–p21 pathway. Significance: It has been recently realized that most currently used chemotherapies exert their therapeutic effect at least partly by induction of terminal cell arrest, senescence. However, the mechanisms by which cell-intrinsic senescence sensitivity is determined are poorly understood. Results of this study identify the E2F1-CIP2A positive feedback loop as a key determinant of breast cancer cell sensitivity to senescence and growth arrest induction. Our data also indicate that this newly characterized interplay between 2 frequently overexpressed oncoproteins constitutes a promising prosenescence target for therapy of cancers with inactivated p53 and p21. Finally, these results may also facilitate novel stratification strategies for selection of patients to receive senescence-inducing cancer therapies. Cancer Discov; 3(2); 182–97. ©2013 AACR. This article is highlighted in the In This Issue feature, p. 125
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“it does not compromise normal mouse development or growth, except for a defect in spermatogenesis [11,22,23]”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [11]
In the citing paper
“CIP2A deficiency inhibits MYC activity, and Her2-driven mammary tumorigenesis in vivo [11,22]”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [11]
In the citing paper
“without lack of any detrimental normal tissue homeostasis effects in a CIP2A-deficient mouse model [11,22,23]”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [11]
In the citing paper
“This is a very important finding because the therapeutic effects of inhibition of CIP2A protein expression have been validated by numerous studies [6 -8,10 -12,21].”
From Oncoprotein CIP2A is stabilized via interaction with tumor suppressor PP2A/B56 (2017) · cites this paper as [11]
In the citing paper
“therapeutic impact of inhibition of CIP2A protein expression has been validated by numerous studies across human cancer types18,20,21,23,33,34.”
From Structural mechanism for inhibition of PP2A-B56α and oncogenicity by CIP2A (2023) · cites this paper as [18]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
METABRIC Group, Curtis, C., Shah, S. P., Chin, S.-F., Turashvili, G., Rueda, O. M., Dunning, M. J., Speed, D., Lynch, A. G., Samarajiwa, S., et al. (2012) · Nature · doi:10.1038/nature10983 · Cited by 6,097 · cited 1×
“Interestingly, deletion of the B55α gene was recently identified as a potential driver mutation specifically in the luminal B type of breast cancer (55).”
BackgroundIn Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, U., Lukacs, C., Klein, C., et al. (2004) · Science · doi:10.1126/science.1092472 · Cited by 4,661 · cited 1×
“Moreover, re-activation of wild-type p53 in MCF-7 human breast cancer cells with small-molecule inhibitors of Mdm2-p53 interaction, Nutlin-3 (31), or RITA (32), inhibited CIP2A expression both at mRNA and protein level (Figure 1D, E and Figure S2A,B).”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“To study whether, in addition to p53 activation (10), the loss of CIP2A also suppresses tumorigenesis, we analyzed mammary tumor initiation and progression in the MMTV neu breast cancer mouse model crossed with CIP2AHOZ mice.”
BackgroundBRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
The essence of senescence: Figure 1.
Kuilman, T., Michaloglou, C., Mooi, W. J., & Peeper, D. S. (2010) · Genes & Development · doi:10.1101/gad.1971610 · Cited by 2,038
Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis
Chen, Z., Trotman, L. C., Shaffer, D., Lin, H.-K., Dotan, Z. A., Niki, M., Koutcher, J. A., Scher, H. I., Ludwig, T., Gerald, W., et al. (2005) · Nature · doi:10.1038/nature03918 · Cited by 1,993
Restoration of p53 function leads to tumour regression in vivo
Ventura, A., Kirsch, D. G., McLaughlin, M. E., Tuveson, D. A., Grimm, J., Lintault, L., Newman, J., Reczek, E. E., Weissleder, R., & Jacks, T. (2007) · Nature · doi:10.1038/nature05541 · Cited by 1,820 · cited 8×
“Immunohistochemical staining for Ki–67 and DcR2 and hematoxylin and eosin (H&E) staining were conducted as previously described (41).”
BackgroundInfluentialAdjuvant Docetaxel or Vinorelbine with or without Trastuzumab for Breast Cancer
Joensuu, H., Kellokumpu-Lehtinen, P.-L., Bono, P., Alanko, T., Kataja, V., Asola, R., Utriainen, T., Kokko, R., Hemminki, A., Tarkkanen, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053028 · Cited by 1,403
Self-citationGuy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., & Muller, W. J. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.22.10578 · Cited by 1,193
Therapy-induced senescence in cancer.
Ewald, J. A., Desotelle, J. A., Wilding, G., & Jarrard, D. F. (2010) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djq364 · Cited by 824 · cited 4×
“Notably, although traditionally considered as apoptosisinducing agents, most of the currently used chemotherapies exert their therapeutic effect at least partly by senescence induction (6, 7).”
BackgroundInfluentialMutant p53 Gain-of-Function in Cancer
Oren, M., & Rotter, V. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001107 · Cited by 753
Small molecule RITA binds to p53, blocks p53–HDM-2 interaction and activates p53 function in tumors
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G. G. C., Masucci, M., Pramanik, A., & Selivanova, G. (2004) · Nature Medicine · doi:10.1038/nm1146 · Cited by 750
Ansieau, S., Bastid, J., Doreau, A., Morel, A.-P., Bouchet, B. P., Thomas, C., Fauvet, F., Puisieux, I., Doglioni, C., Piccinin, S., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.005 · Cited by 715
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 14×
“Taken together, these results suggest that the positive feedback mechanism from CIP2A to E2F1 is mediated by inhibition of the PP2A complex containing the B55α subunit.”
BackgroundResultInfluentialSelf-citationModeling the Therapeutic Efficacy of p53 Restoration in Tumors
Martins, C. P., Brown-Swigart, L., & Evan, G. I. (2006) · Cell · doi:10.1016/j.cell.2006.12.007 · Cited by 600 · cited 2×
“Lymphoma lysates from EmMyc:p53ER mice systemically treated with either tamoxifen or peanut oil were prepared as described previously (33).”
MethodSelf-citationDistinct p53 Transcriptional Programs Dictate Acute DNA-Damage Responses and Tumor Suppression
Brady, C. A., Jiang, D., Mello, S. S., Johnson, T. M., Jarvis, L. A., Kozak, M. M., Broz, D. K., Basak, S., Park, E. J., McLaughlin, M. E., et al. (2011) · Cell · doi:10.1016/j.cell.2011.03.035 · Cited by 533
p53 and E2f: partners in life and death
Polager, S., & Ginsberg, D. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2718 · Cited by 498 · cited 4×
“Recent studies have indicated that E2F1’s classic function in transcriptional activation of S-phase–associated genes only partially explains its oncogenic activity (15, 16).”
BackgroundInfluentialJohnson, D. G., Ohtani, K., & Nevins, J. R. (1994) · Genes & Development · doi:10.1101/gad.8.13.1514 · Cited by 494
Pro-senescence therapy for cancer treatment
Nardella, C., Clohessy, J. G., Alimonti, A., & Pandolfi, P. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3057 · Cited by 437 · cited 4×
“Notably, although traditionally considered as apoptosisinducing agents, most of the currently used chemotherapies exert their therapeutic effect at least partly by senescence induction (6, 7).”
BackgroundInfluentialSkp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence
Lin, H.-K., Chen, Z., Wang, G., Nardella, C., Lee, S.-W., Chan, C.-H., Yang, W.-L., Wang, J., Egia, A., Nakayama, K. I., et al. (2010) · Nature · doi:10.1038/nature08815 · Cited by 400 · cited 3×
“Recent studies have shown that cellular senescence can also be triggered by either p21 induction or E2F1 inhibition in cells carrying mutant p53 (4, 19, 20, 43).”
BackgroundClinical Outcomes and Correlates of TP53 Mutations and Cancer
Robles, A. I., & Harris, C. C. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001016 · Cited by 394
Chk2 activates E2F-1 in response to DNA damage
Stevens, C., Smith, L., & La Thangue, N. B. (2003) · Nature Cell Biology · doi:10.1038/ncb974 · Cited by 385
Alimonti, A., Nardella, C., Chen, Z., Clohessy, J. G., Carracedo, A., Trotman, L. C., Cheng, K., Varmeh, S., Kozma, S. C., Thomas, G., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40535 · Cited by 374
Lysine Methylation Regulates E2F1-Induced Cell Death
Kontaki, H., & Talianidis, I. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.06.006 · Cited by 353
Multiple pathways regulated by the tumor suppressor PP2A in transformation
Westermarck, J., & Hahn, W. C. (2008) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2008.02.001 · Cited by 344 · cited 9×
“Taken together, these results suggest that the positive feedback mechanism from CIP2A to E2F1 is mediated by inhibition of the PP2A complex containing the B55α subunit.”
BackgroundInfluentialSelf-citationPRAK Is Essential for ras-Induced Senescence and Tumor Suppression
Sun, P., Yoshizuka, N., New, L., Moser, B. A., Li, Y., Liao, R., Xie, C., Chen, J., Deng, Q., Yamout, M., et al. (2007) · Cell · doi:10.1016/j.cell.2006.11.050 · Cited by 321 · cited 1×
“The functional relevance of spontaneous senescence induction in preventing tumor initiation and progression has been demonstrated by several recent mouse studies (3-5).”
BackgroundLane, D. P., Cheok, C. F., & Lain, S. (2010) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a001222 · Cited by 246
CIP2A Is Associated with Human Breast Cancer Aggressivity
Côme, C., Laine, A., Chanrion, M., Edgren, H., Mattila, E., Liu, X., Jonkers, J., Ivaska, J., Isola, J., Darbon, J.-M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3283 · Cited by 221
Self-citationGroth-Pedersen, L., Ostenfeld, M. S., Høyer-Hansen, M., Nylandsted, J., & Jäättelä, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3520 · Cited by 215
Hoo, L. S., Zhang, J. Y., & Chan, E. K. (2002) · Oncogene · doi:10.1038/sj.onc.1205625 · Cited by 201 · cited 1×
“Immunohistochemical and statistical analysis of human breast cancer patient samples CIP2A immunostaining in both FinProg and in FinHer breast cancer patient cohorts were performed by polyclonal rabbit antibody (58).”
MethodSelf-citationKim, K. S., Seu, Y. B., Baek, S.-H., Kim, M. J., Kim, K. J., Kim, J. H., & Kim, J.-R. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-03-0280 · Cited by 199 · cited 1×
“functionally involved in p53-induced senescence (36-38)(Figure 3G).”
Sihto, H., Kukko, H., Koljonen, V., Sankila, R., Böhling, T., & Joensuu, H. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3363 · Cited by 186
Self-citationMYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Khanna, A., Böckelman, C., Hemmes, A., Junttila, M. R., Wiksten, J.-P., Lundin, M., Junnila, S., Murphy, D. J., Evan, G. I., Haglund, C., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp103 · Cited by 185 · cited 7×
“It is possible that in these cases CIP2A overexpression is due to high expression of MYC or ETS1 transcription factors, both shown recently to stimulate CIP2A expression in human cancer cells (24, 30).”
BackgroundInfluentialSelf-citationRegulation of E2Fs and senescence by PML nuclear bodies
Vernier, M., Bourdeau, V., Gaumont-Leclerc, M.-F., Moiseeva, O., Bégin, V., Saad, F., Mes-Masson, A.-M., & Ferbeyre, G. (2011) · Genes & Development · doi:10.1101/gad.1975111 · Cited by 177
Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence
Larsson, L. (2011) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.10.005 · Cited by 175
Mechanisms of MYC stabilization in human malignancies
Junttila, M. R., & Westermarck, J. (2008) · Cell Cycle · doi:10.4161/cc.7.5.5492 · Cited by 144
Self-citationLi, W., Ge, Z., Liu, C., Liu, Z., Björkholm, M., Jia, J., & Xu, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4137 · Cited by 142
Lucas, C. M., Harris, R. J., Giannoudis, A., Copland, M., Slupsky, J. R., & Clark, R. E. (2011) · Blood · doi:10.1182/blood-2010-08-304477 · Cited by 138
Molecular Subtypes of Breast Cancers Detected in Mammography Screening and Outside of Screening
Sihto, H. J., Lundin, J. E., Lehtimäki, T., Sarlomo‐Rikala, M., Bützow, R. C., Holli, K., Sailas, L., Kataja, V. V., Lundin, M., Turpeenniemi-Hujanen, T. M., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5003 · Cited by 131
Self-citationSwarbrick, A., Roy, E., Allen, T., & Bishop, J. M. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0801505105 · Cited by 113
p21 delays tumor onset by preservation of chromosomal stability
Barboza, J. A., Liu, G., Ju, Z., El-Naggar, A. K., & Lozano, G. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606343104 · Cited by 110
neu/ERBB2 Cooperates with p53-172H during Mammary Tumorigenesis in Transgenic Mice
Li, B., Rosen, J. M., McMenamin-Balano, J., Muller, W. J., & Perkins, A. S. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.6.3155 · Cited by 105
Overexpression and Small Molecule-Triggered Downregulation of CIP2A in Lung Cancer
Ma, L., Wen, Z.-S., Liu, Z., Hu, Z., Ma, J., Chen, X.-Q., Liu, Y.-Q., Pu, J.-X., Xiao, W.-L., Sun, H.-D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020159 · Cited by 96
Evolving intricacies and implications of E2F1 regulation
Mundle, S. D., & Saberwal, G. (2003) · The FASEB Journal · doi:10.1096/fj.02-0431rev · Cited by 84
Maehara, K., Yamakoshi, K., Ohtani, N., Kubo, Y., Takahashi, A., Arase, S., Jones, N., & Hara, E. (2005) · The Journal of Cell Biology · doi:10.1083/jcb.200411093 · Cited by 83
Niemelä, M., Kauko, O., Sihto, H., Mpindi, J.-P., Nicorici, D., Pernilä, P., Kallioniemi, O.-P., Joensuu, H., Hautaniemi, S., & Westermarck, J. (2012) · Oncogene · doi:10.1038/onc.2011.599 · Cited by 79
Self-citationLodygin, D., Menssen, A., & Hermeking, H. (2002) · Journal of Clinical Investigation · doi:10.1172/jci16588 · Cited by 74
Activator Protein-1 Mediates Induced but not Basal Epidermal Growth Factor Receptor Gene Expression
Johnson, A. C., Murphy, B. A., Matelis, C. M., Rubinstein, Y., Piebenga, E. C., Akers, L. M., Neta, G., Vinson, C., & Birrer, M. (2000) · Molecular Medicine · doi:10.1007/bf03401931 · Cited by 72
Huang, B., Deo, D., Xia, M., & Vassilev, L. T. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0144 · Cited by 72
Helmbold, H., Komm, N., Deppert, W., & Bohn, W. (2009) · Oncogene · doi:10.1038/onc.2009.222 · Cited by 68
Khanna, A., Okkeri, J., Bilgen, T., Tiirikka, T., Vihinen, M., Visakorpi, T., & Westermarck, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017979 · Cited by 67
Self-citationLow E2F1 transcript levels are a strong determinant of favorable breast cancer outcome
Vuaroqueaux, V., Urban, P., Labuhn, M., Delorenzi, M., Wirapati, P., Benz, C. C., Flury, R., Dieterich, H., Spyratos, F., Eppenberger, U., et al. (2007) · Breast Cancer Research · doi:10.1186/bcr1681 · Cited by 64
Li, Q., Tang, L., Roberts, P. C., Kraniak, J. M., Fridman, A. L., Kulaeva, O. I., Tehrani, O. S., & Tainsky, M. A. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0114 · Cited by 63
E2F-1 is a critical modulator of cellular senescence in human cancer
Park, C., Lee, I., & Kang, W. K. (2006) · International Journal of Molecular Medicine · doi:10.3892/ijmm.17.5.715 · Cited by 61
p53-dependent senescence delays Eμ-myc-induced B-cell lymphomagenesis
Post, S. M., Quintás-Cardama, A., Terzian, T., Smith, C., Eischen, C. M., & Lozano, G. (2010) · Oncogene · doi:10.1038/onc.2009.423 · Cited by 58
CIP2A promotes proliferation of spermatogonial progenitor cells and spermatogenesis in mice
Ventelä, S., Côme, C., Mäkelä, J.-A., Hobbs, R. M., Mannermaa, L., Kallajoki, M., Chan, E. K., Pandolfi, P. P., Toppari, J., & Westermarck, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0033209 · Cited by 58 · cited 2×
“CIP2A Inactivation Induces Senescence and Growth Arrest and Restricts Tumorigenesis in a Breast Cancer Mouse Model We have recently generated a CIP2A hypomorphic mouse model (CIP2AHOZ) using gene trap technology (44).”
MethodSelf-citationIncrease in CIP2A expression is associated with doxorubicin resistance
Choi, Y. A., Park, J. S., Park, M. Y., Oh, K. S., Lee, M. S., Lim, J.-S., Kim, K. I., Kim, K.-Y., Kwon, J., Yoon, D. Y., et al. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.01.018 · Cited by 54
Mathiasen, D. P., Egebjerg, C., Andersen, S. H., Rafn, B., Puustinen, P., Khanna, A., Daugaard, M., Valo, E., Tuomela, S., Bøttzauw, T., et al. (2012) · Oncogene · doi:10.1038/onc.2011.230 · Cited by 44
Self-citationEfficacy and Tolerability of Vinorelbine in the Cancer Therapy
Galano, G., Caputo, M., Tecce, M. F., & Capasso, A. (2011) · Current Drug Safety · doi:10.2174/157488611797579302 · Cited by 36
Kellokumpu‐Lehtinen, P., Sunela, K. L., Lehtinen, I., Joensuu, H., & Sjöström-Mattson, J. (2006) · Clinical Breast Cancer · doi:10.3816/cbc.2006.n.057 · Cited by 19
Self-citation
Cited by
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Khanna, A., Pimanda, J. E., & Westermarck, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1994 · Cited by 154
“40% of unselected patient populations (8, 11, 16).”
BackgroundInfluentialSelf-citationPP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells
Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aaq1093 · Cited by 149
Self-citationMechanisms and significance of therapy-induced and spontaneous senescence of cancer cells
Mikuła-Pietrasik, J., Niklas, A., Uruski, P., Tykarski, A., & Książek, K. (2020) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03261-8 · Cited by 119
Vainonen, J. P., Momeny, M., & Westermarck, J. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abe2967 · Cited by 104
Self-citation
Metadata
- Authors
- Laine, A., Sihto, H., Come, C., Rosenfeldt, M. T., Zwolinska, A., Niemelä, M., Khanna, A., Chan, E. K., Kähäri, V.-M., Kellokumpu-Lehtinen, P.-L., Sansom, O. J., Evan, G. I., Junttila, M. R., Ryan, K. M., Marine, J.-C., Joensuu, H., & Westermarck, J.
- Affiliations
- Åbo Akademi University (FI)
- Authors' Affiliations: 1Turku Centre for Biotechnology, University of Turku and Åbo Akademi University, and 2Turku Doctoral Program of Biomedical Sciences, University of Turku; Departments of 3Pathology, 4Medical Biochemistry and Genetics, and 5Dermatology, University of Turku and Turku University Hospital, MediCity Research Laboratory, University of Turku, Turku, 6Laboratory of Molecular Oncology, Molecular Cancer Biology Program, Biomedicum, and 7Department of Oncology, Helsinki University Central Hospital, University of Helsinki, Helsinki; 8Institute of Biomedical Technology and 9Department of Oncology, University of Tampere and Tampere University Hospital, Tampere, Finland; 10The Beatson Institute for Cancer Research, Glasgow, United Kingdom; 11Laboratory for Molecular Cancer Biology, Center for Human Genetics and VIB11—Center for the Biology of Disease, VIB-KULeuven, Leuven, Belgium; 12Department of Oral Biology, University of Florida, Gainesville, Florida; and 13Department of Pathology and Helen Diller
- Corresponding author
- Westermarck, Jukka
- ORCID
- Venue
- Cancer Discovery
- Published
- 2013-02-01
- Volume
- 3
- Issue
- 2
- Pages
- 182-197
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC3572190
- OpenAlex
- W2099186537
- Cited by
- 130
- References
- 62
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 2 · 2023: 15 · 2022: 7 · 2021: 12 · 2020: 10 · 2019: 8 · 2018: 13 · 2017: 10 · 2016: 7 · 2015: 17 · 2014: 9 · 2013: 10
- FWCI
- 9.95
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-05-01)
- Open access
- green
- europepmc.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- Funders
- Cancer Research UK (A10419, 12481, 15816)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- cellular senescence, breast cancer, CIP2A, E2F1, positive feedback loop, p53 inactivation, p21, protein phosphatase 2A, senescence resistance, mammary carcinogenesis, prognostic factors
- MeSH terms
- Docetaxel, Vinorelbine, Animals, Antinematodal Agents, Autoantigens, Breast Neoplasms, Embryo, Mammalian, Female, Fibroblasts, Humans, Membrane Proteins, Vinblastine, Blotting, Western, Mammary Neoplasms, Animal, Tumor Suppressor Protein p53, Cellular Senescence, Mice, Knockout, Drug Resistance, Neoplasm, Reverse Transcriptase Polymerase Chain Reaction, Feedback, Physiological, Taxoids, HCT116 Cells, Cell Line, Tumor, Intracellular Signaling Peptides and Proteins, Cell Proliferation, E2F1 Transcription Factor, Cyclin-Dependent Kinase Inhibitor p21, Mice, MCF-7 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.